{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:43:29Z","timestamp":1793825009232,"version":"4.6.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01700-2","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T02:02:34Z","timestamp":1741226554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["TREM2 risk variants and associated endophenotypes\u00a0in alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Janna I. R.","family":"Dijkstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vermunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Venkatraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgii","family":"Ozhegov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Coomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hulsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa M.","family":"de Geus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sietske A. M.","family":"Sikkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Tijms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida A.","family":"Gouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard G. B.","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande A. L.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henne","family":"Holstege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven J.","family":"van der Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"2","key":"1700_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 Associated with the Risk of Alzheimer\u2019s Disease. N Engl J Med. 2013Jan 10;368(2):107\u201323.","journal-title":"N Engl J Med"},{"issue":"2","key":"1700_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 Variants in Alzheimer\u2019s Disease. N Engl J Med. 2013Jan 1;368(2):117.","journal-title":"N Engl J Med"},{"key":"1700_CR3","doi-asserted-by":"crossref","unstructured":"Holstege H, Hulsman M, Charbonnier C, Grenier-Boley B, Quenez O, Grozeva D, et al. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer\u2019s disease. Nat Genet. 2022;54:1786\u201394.","DOI":"10.1038\/s41588-022-01208-7"},{"issue":"28","key":"1700_CR4","first-page":"1293","volume":"22","author":"R Sherva","year":"2022","unstructured":"Sherva R, Zhang R, Sahelijo N, Jun G, Anglin T, Chanfreau C, et al. African ancestry GWAS of dementia in a large military cohort identifies significant risk loci. Mol Psychiatry. 2022Dec;22(28):1293\u2013302.","journal-title":"Mol Psychiatry"},{"key":"1700_CR5","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41380-018-0112-7","volume":"24","author":"JC Bis","year":"2020","unstructured":"Bis JC, Jian X, Kunkle BW, Chen Y, Hamilton-Nelson KL, Bush WS, et al. Whole exome sequencing study identifies novel rare and common Alzheimer\u2019s-Associated variants involved in immune response and transcriptional regulation. Mol Psychiatry. 2020;24:1859\u201375.","journal-title":"Mol Psychiatry"},{"issue":"9","key":"1700_CR6","first-page":"1373","volume":"49","author":"R Sims","year":"2017","unstructured":"Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer\u2019s disease. Nat Publ Group. 2017Sep;49(9):1373\u201387.","journal-title":"Nat Publ Group"},{"key":"1700_CR7","doi-asserted-by":"crossref","unstructured":"Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer\u2019s disease. Mol Neurodegener. BioMed Central Ltd.; 2018;13(1):66.","DOI":"10.1186\/s13024-018-0298-9"},{"key":"1700_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland TK, Colonna M. TREM2 \u2014 a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018Nov;14:667\u201375.","journal-title":"Nat Rev Neurol"},{"issue":"10284","key":"1700_CR9","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021Apr 24;397(10284):1577\u201390.","journal-title":"Lancet"},{"issue":"4","key":"1700_CR10","first-page":"575","volume":"1","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimer\u2019s and Dementia: Translational Research and Clinical Interventions. 2018Jan;1(4):575\u201390.","journal-title":"Alzheimer\u2019s and Dementia: Translational Research and Clinical Interventions"},{"key":"1700_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41593-022-01240-0","volume":"26","author":"B Lengerich","year":"2023","unstructured":"Lengerich B, Zhan L, Xia D, Chan D, Joy D, Park JI, et al. A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer\u2019s disease models. Nat Neurosci. 2023;26:416\u201329.","journal-title":"Nat Neurosci"},{"key":"1700_CR12","doi-asserted-by":"crossref","unstructured":"Li RY, Qin Q, Yang HC, Wang YY, Mi YX, Yin YS, et al. TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target.\u00a0Mol Neurodegener. BioMed Central Ltd; 2022;17(1):40.","DOI":"10.1186\/s13024-022-00542-y"},{"key":"1700_CR13","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1038\/s41380-021-01083-4","volume":"26","author":"G Cisbani","year":"2021","unstructured":"Cisbani G, Rivest S. Targeting innate immunity to protect and cure Alzheimer\u2019s disease: opportunities and pitfalls. Mol Psychiatry. 2021;26:5504\u201315.","journal-title":"Mol Psychiatry"},{"key":"1700_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021Mar;17:157\u201372.","journal-title":"Nat Rev Neurol"},{"key":"1700_CR15","doi-asserted-by":"crossref","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2024. Vol. 10, Alzheimer\u2019s and Dementia: Translational Research and Clinical Interventions.\u00a0Alzheimers Dement (N Y). Wiley; 2024;10(2):e12465.","DOI":"10.1002\/trc2.12465"},{"issue":"Suppl 6","key":"1700_CR16","volume":"20","author":"C Mirescu","year":"2025","unstructured":"Mirescu C. Characterization of the first TREM2 small molecule agonist, VG-3927, for clinical development in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2025Dec 9;20(Suppl 6): e084622.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"1700_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00401-022-02495-4","volume":"144","author":"B Kim","year":"2022","unstructured":"Kim B, Suh E, Nguyen AT, Prokop S, Mikytuck B, Olatunji OA, et al. TREM2 risk variants are associated with atypical Alzheimer\u2019s disease. Acta Neuropathol. 2022;144:1085\u2013102.","journal-title":"Acta Neuropathol"},{"key":"1700_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-019-02048-2","volume":"138","author":"S Prokop","year":"2019","unstructured":"Prokop S, Miller KR, Labra SR, Pitkin RM, Hoxha K, Narasimhan S, et al. Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer\u2019s disease patient brain samples. Acta Neuropathol. 2019;138:613\u201330.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"1700_CR19","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1016\/j.neurobiolaging.2014.06.007","volume":"35","author":"E Luis","year":"2014","unstructured":"Luis E, Ortega-Cubero S, Lamet I, Razquin C, Cruchaga C, Benitez B, et al. Frontobasal gray matter loss is associated with the TREM2 p.R47H. Neurobiological Aging. 2014;35(12):2681\u201390.","journal-title":"Neurobiological Aging."},{"key":"1700_CR20","doi-asserted-by":"publisher","unstructured":"Das M, Mao W, Voskobiynyk Y, Necula D, Lew I, Petersen C, et al. Alzheimer risk-increasing TREM2 variant causes aberrant cortical synapse density and promotes network hyperexcitability in mouse models.\u00a0Neurobiol Dis. 2023;186:106263. https:\/\/doi.org\/10.1016\/j.nbd.2023.106263.\u00a0","DOI":"10.1016\/j.nbd.2023.106263"},{"key":"1700_CR21","doi-asserted-by":"publisher","unstructured":"Devi G, Scheltens P. Heterogeneity of Alzheimer\u2019s disease: Consequence for drug trials? Alz Res Therapy. BioMed Central Ltd.; 2018;10:122.\u00a0https:\/\/doi.org\/10.1186\/s13195-018-0455-y.","DOI":"10.1186\/s13195-018-0455-y"},{"key":"1700_CR22","first-page":"12","volume":"2","author":"TR Jay","year":"2017","unstructured":"Jay TR, Von Saucken VE, Landreth GE. TREM2 in Neurodegenerative Diseases. Mol Neurodegener. 2017Aug;2:12.","journal-title":"Mol Neurodegener"},{"key":"1700_CR23","doi-asserted-by":"publisher","unstructured":"Fancy N, Willumsen N, Tsartsalis S, Khozoie C, Mcgarry A, Muirhead RC, et al. Mechanisms contributing to differential genetic risks for TREM2 R47H and R62H variants in Alzheimer\u2019s Disease.\u00a0medRxiv. 2022.\u00a0https:\/\/doi.org\/10.1101\/2022.07.12.22277509.","DOI":"10.1101\/2022.07.12.22277509"},{"key":"1700_CR24","first-page":"1","volume":"5","author":"DL Kober","year":"2016","unstructured":"Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Biophysics and Structural Biology. 2016;5:1\u201324.","journal-title":"Biophysics and Structural Biology"},{"issue":"4","key":"1700_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jalz.2016.07.004","volume":"13","author":"W Song","year":"2017","unstructured":"Song W, Hooli B, Mullin K, Chih Jin S, Cella M, Ulland TK, et al. Alzheimer\u2019s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimer\u2019s Dementia. 2017;13(4):381\u20137.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"1700_CR26","doi-asserted-by":"crossref","unstructured":"Del-Aguila JL, Benitez BA, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, et al. TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers.\u00a0Mol Neurodegener.\u00a02019;14(18):1\u201313.","DOI":"10.1186\/s13024-019-0319-3"},{"key":"1700_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","volume":"4","author":"BM Tijms","year":"2024","unstructured":"Tijms BM, Vromen EM, Mjaavatten O, Holstege H, Reus LM, van der Lee S, et al. Large-scale cerebrospinal fluid proteomic analysis in Alzheimer\u2019s disease patients reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging. 2024;4:33\u201347.","journal-title":"Nat Aging"},{"issue":"6","key":"1700_CR28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jalz.2014.05.1751","volume":"10","author":"CF Slattery","year":"2014","unstructured":"Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer\u2019s disease but not of prion or frontotemporal dementia. Alzheimer\u2019s & Dementia. 2014Nov 1;10(6):602\u20138.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"12","key":"1700_CR29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jalz.2014.12.009","volume":"11","author":"CM Lill","year":"2015","unstructured":"Lill CM, Rengmark A, Pihlstr\u00f8m L, Fogh I, Shatunov A, Sleiman PM, et al. The role of TREM2 R47H as a risk factor for Alzheimer\u2019s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson\u2019s disease. Alzheimer\u2019s and Dementia. 2015Dec 1;11(12):1407\u201316.","journal-title":"Alzheimer\u2019s and Dementia"},{"issue":"6","key":"1700_CR30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jalz.2014.05.1751","volume":"10","author":"C Slattery","year":"2014","unstructured":"Slattery C, Beck J, Harper L, Adamson G, Abdi Z, Campbell T, et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer\u2019s disease but not of prion or frontotemporal dementia. Alzheimers Dementia. 2014Nov;10(6):602\u20138.","journal-title":"Alzheimers Dementia"},{"issue":"8","key":"1700_CR31","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s and Dementia. 2024Aug 1;20(8):5143\u201369.","journal-title":"Alzheimer\u2019s and Dementia"},{"issue":"3","key":"1700_CR32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"FWM Van Der","year":"2018","unstructured":"Van Der FWM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer\u2019s Disease. 2018Jan 1;62(3):1091\u2013111.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"1700_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54:412\u201336.","journal-title":"Nat Genet"},{"key":"1700_CR34","doi-asserted-by":"publisher","unstructured":"Das S, Forer L, Sch\u00f6nherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods.\u00a0Nat Genet. 2016;48(10):1284\u20137. https:\/\/doi.org\/10.1038\/ng.3656.\u00a0","DOI":"10.1038\/ng.3656"},{"key":"1700_CR35","doi-asserted-by":"publisher","unstructured":"Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.\u00a0Nature. 2021;590:290\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03205-y.","DOI":"10.1038\/s41586-021-03205-y"},{"key":"1700_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41431-018-0273-5","volume":"27","author":"N Tesi","year":"2019","unstructured":"Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, Van SN, et al. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer\u2019s disease. Eur J Hum Genet. 2019;27:244\u201353.","journal-title":"Eur J Hum Genet"},{"key":"1700_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-023-00687-4","volume":"19","author":"L Wang","year":"2024","unstructured":"Wang L, Nyk\u00e4nen NP, Western D, Gorijala P, Timsina J, Li F, et al. Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer\u2019s disease. Mol Neurodegener. 2024;19:1.","journal-title":"Mol Neurodegener"},{"key":"1700_CR38","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis NM, Rothstein JH, Pejaver V, Middha S, Mcdonnell SK, Baheti S, et al. An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. The American Journal of Human Genetics. 2016;99:877\u201385.","journal-title":"The American Journal of Human Genetics"},{"issue":"3","key":"1700_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975Nov 1;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"key":"1700_CR40","doi-asserted-by":"publisher","unstructured":"Dubbelman MA, Hendriksen HMA, Harrison JE, Vijverberg EGB, Prins ND, Kroeze LA, et al. Cognitive and Functional Change over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.\u00a0Neurology. 2024;102(2):e207978. https:\/\/doi.org\/10.1212\/WNL.0000000000207978.","DOI":"10.1212\/WNL.0000000000207978"},{"issue":"3","key":"1700_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, Van Berckel BNM, et al. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-B 1\u201342. Clin Chem. 2018;64(3):576\u201385.","journal-title":"Clin Chem"},{"issue":"6","key":"1700_CR42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","volume":"10","author":"FH Duits","year":"2014","unstructured":"Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid \u201calzheimer profile\u201d: Easily said, but what does it mean? Alzheimer\u2019s and Dementia. 2014Nov 1;10(6):713-723.e2.","journal-title":"Alzheimer\u2019s and Dementia"},{"issue":"11","key":"1700_CR43","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","volume":"14","author":"SE Schindler","year":"2018","unstructured":"Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer\u2019s and Dementia. 2018Nov 1;14(11):1460\u20139.","journal-title":"Alzheimer\u2019s and Dementia"},{"issue":"10","key":"1700_CR44","first-page":"563","volume":"1","author":"EAJ Willemse","year":"2018","unstructured":"Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer\u2019s disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer\u2019s and Dementia: Diagnosis, Assessment and Disease Monitoring. 2018Jan;1(10):563\u201372.","journal-title":"Alzheimer\u2019s and Dementia: Diagnosis, Assessment and Disease Monitoring"},{"issue":"11","key":"1700_CR45","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/acn3.51676","volume":"9","author":"L Vermunt","year":"2022","unstructured":"Vermunt L, Otte M, Verberk IMW, Killestein J, Lemstra AW, van der Flier WM, et al. Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Ann Clin Transl Neurol. 2022Nov 1;9(11):1832\u20137.","journal-title":"Ann Clin Transl Neurol"},{"key":"1700_CR46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"21","key":"1700_CR47","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1007\/s00330-011-2205-4","volume":"18","author":"ELGE Koedam","year":"2011","unstructured":"Koedam ELGE, Lehmann M, Van Der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiology. 2011Mar;18(21):2618\u201325.","journal-title":"Eur Radiology"},{"issue":"2","key":"1700_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. American Journal of Roentgenology. 1987;149(2):351\u20136.","journal-title":"American Journal of Roentgenology."},{"issue":"5","key":"1700_CR49","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/acn3.51339","volume":"8","author":"CT Briels","year":"2021","unstructured":"Briels CT, Stam CJ, Scheltens P, Gouw AA. The predictive value of normal EEGs in dementia due to Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2021May 1;8(5):1038\u201348.","journal-title":"Ann Clin Transl Neurol"},{"key":"1700_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000182422","volume":"27","author":"M Liedorp","year":"2009","unstructured":"Liedorp M, Van Der Flier WM, Hoogervorst ELJ, Scheltens P, Stam CJ. Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort. Original Research Article Dement Geriatr Cogn Disord. 2009;27:18\u201323.","journal-title":"Original Research Article Dement Geriatr Cogn Disord"},{"issue":"2","key":"1700_CR51","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B. FreeSurfer Neuroimage. 2012Aug 15;62(2):774\u201381.","journal-title":"FreeSurfer Neuroimage"},{"key":"1700_CR52","doi-asserted-by":"publisher","unstructured":"Archetti D, Venkatraghavan V, Weiss B, Bourgeat P, Auer T, Vidny\u00e1nszky Z, et al. A machine-learning model to harmonize brain volumetric data for quantitative neuro-radiological. medRxiv.\u00a0Radiol Artif Intell.\u00a02025;7(1):e240030. https:\/\/doi.org\/10.1148\/ryai.240030.","DOI":"10.1148\/ryai.240030"},{"key":"1700_CR53","doi-asserted-by":"crossref","unstructured":"Bocancea DI, den Braber A, Jiang C, Coomans EM, van Unnik AAJM, van Veen JML, et al. Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort. Alzheimer\u2019s & Dementia.\u00a02023;19(Suppl. 10):1\u20133,e081841.","DOI":"10.1002\/alz.081841"},{"issue":"167","key":"1700_CR54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuroimage.2017.11.024","volume":"15","author":"JP Fortin","year":"2018","unstructured":"Fortin JP, Cullen N, Sheline YI, Taylor WD, Aselcioglu I, Cook PA, et al. Harmonization of cortical thickness measurements across scanners and sites. Neuroimage. 2018Feb;15(167):104\u201320.","journal-title":"Neuroimage"},{"key":"1700_CR55","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1007\/s00259-020-04831-w","volume":"47","author":"D Visser","year":"2020","unstructured":"Visser D, Wolters EE, J Verfaillie SC, Coomans EM, Timmers T, Tuncel H, et al. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47:3165\u201375.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1700_CR56","doi-asserted-by":"publisher","unstructured":"Wolters EE, van de Beek M, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, et al. Tau PET and relative cerebral blood flow in Dementia with Lewy bodies: A PET study. NeuroImage: Clinical. 2020;28. https:\/\/doi.org\/10.1016\/j.nicl.2020.102504.","DOI":"10.1016\/j.nicl.2020.102504"},{"key":"1700_CR57","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s11307-017-1080-z","volume":"19","author":"SSV Golla","year":"2017","unstructured":"Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, et al. Quantification of Tau Load Using [18 F]AV1451 PET. Mol Imaging Biol. 2017;19:963\u201371.","journal-title":"Mol Imaging Biol"},{"key":"1700_CR58","doi-asserted-by":"crossref","unstructured":"Coomans EM, de Koning LA, Rikken RM, Verfaillie SC, Visser D, den Braber A, et al. Performance of a [ 18 F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies.\u00a0Neurology. 2023;101:1850\u201362.","DOI":"10.1212\/WNL.0000000000207794"},{"key":"1700_CR59","doi-asserted-by":"publisher","unstructured":"Singleton E, Hansson O, Pijnenburg YAL, Joie R La, Mantyh WG, Tideman P, et al. Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2021;92(8):872\u201380. https:\/\/doi.org\/10.1136\/jnnp-2020-325497.","DOI":"10.1136\/jnnp-2020-325497"},{"key":"1700_CR60","unstructured":"R: A language and environment for statistical computing. 2023. Available from: https:\/\/www.R-project.org\/"},{"key":"1700_CR61","unstructured":"2023. Python. Available from: https:\/\/www.python.org\/"},{"key":"1700_CR62","unstructured":"Verhage F. Intelligentie en leeftijd bij volwassenen en bejaarden. Groningen: Koninklijke Van Gorcum; 1964. p. 98."},{"key":"1700_CR63","unstructured":"European Commission. International Standard Classification of Education (ISCED). 2023. Available from: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=International_Standard_Classification_of_Education_(ISCED)"},{"key":"1700_CR64","doi-asserted-by":"publisher","unstructured":"The 1000 Genomes Project Consortium. A global reference for human genetic variation.\u00a0Nature. 2015;526(7571):68\u201374. https:\/\/doi.org\/10.1038\/nature15393.","DOI":"10.1038\/nature15393"},{"key":"1700_CR65","doi-asserted-by":"crossref","unstructured":"Gamberger D, Lavra\u010d N, Srivatsa S, Tanzi RE, Doraiswamy PM. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer\u2019s disease. Scientific Reports 2017 7:1. 2017 Jul 28;7(1):1\u201312.","DOI":"10.1038\/s41598-017-06624-y"},{"key":"1700_CR66","unstructured":"gnomAD v4.1.0. Genome Aggregation Database. 2024. Available from: https:\/\/gnomad.broadinstitute.org\/"},{"key":"1700_CR67","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1212\/WNL.0000000000007967","volume":"93","author":"Y Qiu","year":"2019","unstructured":"Qiu Y, Jacobs DM, Messer K, Salmon DP, Feldman HH, SM Alzheimer\u2019s Disease, et al. Cognitive heterogeneity in probable Alzheimer disease. Neurology. 2019;93:778\u201390.","journal-title":"Neurology."},{"key":"1700_CR68","doi-asserted-by":"publisher","unstructured":"Mandal PK, Joshi J, Saharan S. Visuospatial perception: An emerging biomarker for Alzheimer\u2019s disease.\u00a0J Alzheimers Dis. 2012:31 Suppl 3:S117\u201335. https:\/\/doi.org\/10.3233\/JAD-2012-120901.","DOI":"10.3233\/JAD-2012-120901"},{"issue":"1","key":"1700_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/B:CEMN.0000012721.08168.ee","volume":"24","author":"MM Bianchin","year":"2004","unstructured":"Bianchin MM, Capella HM, Chaves DL, Steindel M, Grisard EC, Ganev GG, et al. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol. 2004;24(1):1\u201324.","journal-title":"Cell Mol Neurobiol."},{"issue":"2","key":"1700_CR70","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuron.2013.02.026","volume":"78","author":"C Cruchaga","year":"2013","unstructured":"Cruchaga C, Kauwe JSK, Harari O, Jin SC, Cai Y, Karch CM, et al. GWAS of cerebrospinal fluid tau levels identifies novel risk variants for Alzheimer\u2019s disease. Neuron. 2013Apr 4;78(2):256\u201368.","journal-title":"Neuron"},{"issue":"6","key":"1700_CR71","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00401-016-1630-5","volume":"132","author":"E Sanchez-Mejias","year":"2016","unstructured":"Sanchez-Mejias E, Navarro V, Jimenez S, Sanchez-Mico M, Sanchez-Varo R, Nu\u00f1ez-Diaz C, et al. Soluble phospho-tau from Alzheimer\u2019s disease hippocampus drives microglial degeneration. Acta Neuropathol. 2016Dec 1;132(6):897\u2013916.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"1700_CR72","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022Nov 1;28(11):2381\u20137.","journal-title":"Nat Med"},{"key":"1700_CR73","doi-asserted-by":"crossref","unstructured":"Stephanie J. B. Vos, Frans Verhey, Lutz Fr\u00f6lich, Johannes Kornhuber, Jens Wiltfang, Wolfgang Maier, et al. New criteria for Alzheimer\u2019s disease: Which, when and why? Brain. 2015 May 1;138(5):1134\u20137.","DOI":"10.1093\/brain\/awv055"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01700-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01700-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01700-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:02:14Z","timestamp":1790470934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01700-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01700-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.17.24315643","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: Missing Supplementary file was added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Medical Ethical Committee of Amsterdam UMC, location VUmc. All patients provided written informed consent for their clinical data to be used for research purposes. Consent was obtained according to the Declaration of Helsinki.","order":1,"name":"Ethics","label":"<b>Ethics approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.L. is part of the GeneMINDS consortium, which is powered by Health~Holland, Top Sector Life Sciences & Health and receives co-financing from Vigil Neuroscience, Prevail therapeutics and Brain Research Center. All funding is paid to his institution. L.V. is supported by grant funding\/collaborative study and consultancy\/speaker fees from ZonMw (VENI grant), Amsterdam UMC (Startergrant) Stichting Dioraphte (biobank DemenTree), Olink, Lilly, and Roche; all paid to her institution.Research programs of W.F. have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. W.F. holds the Pasman chair. W.F. is recipient of TAP-dementia (www.tap-dementia.nl), receiving funding from ZonMw (#10510032120003). TAP-dementia receives co-financing from Avid Radiopharmaceuticals and Amprion. All funding is paid to her institution. W.F. has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. All funding is paid to her institution. W.F. is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. All funding is paid to her institution. W.F. participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. W.F. is member of the steering committee of EVOKE\/EVOKE+ (NovoNordisk). All funding is paid to her institution. W.F. is member of the steering committee of PAVE, and Think Brain Health. W.F. was associate editor of Alzheimer, Research & Therapy in 2020\/2021. W.F. is associate editor at Brain.R.O. has received research funding from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer\u2019s fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden (all paid to the institutions). R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, and has given lectures in symposia sponsored by GE Healthcare. He is an advisory board member for Asceneuron and Bristol Myers Squibb. All the aforementioned has been paid to the institutions. He is an editorial board member of Alzheimer\u2019s Research & Therapy and the European Journal of Nuclear Medicine and Molecular Imaging.F.B. is Steering committee or Data Safety Monitoring Board member for Biogen, Merck, Eisai and Prothena. F.B. is advisory board member for Combinostics, Scottish Brain Sciences. F.B. is consultant for Roche, Celltrion, Rewind Therapeutics, Merck, Bracco. F.B. has research agreements with ADDI, Merck, Biogen, GE Healthcare, Roche. F.B. is co-founder and shareholder of Queen Square Analytics LTD.","order":2,"name":"Ethics","label":"<b>Competing interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"57"}}